Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24
IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Eu...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Recursos: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/25248 |
| Acesso em linha: | https://hdl.handle.net/20.500.13003/25248 |
| Access Level: | acceso abierto |
| Palavra-chave: | Adolescent Adult Aged Child Child, Preschool Europe Female Humans Infant Influenza A Virus, H1N1 Subtype Influenza B virus Influenza Vaccines Influenza, Human Male Middle Aged Primary Health Care Vaccination Vaccine Efficacy Young Adult Adolescente Adulto Anciano Niño Preescolar Europa (Continente) Femenino Humanos Lactante Subtipo H1N1 del Virus de la Influenza A Virus de la Influenza B Vacunas contra la Influenza Gripe Humana Masculino Persona de Mediana Edad Atención Primaria de Salud Vacunación Eficacia de las Vacunas Adulto Joven Influenza case-control study imprinting influenza vaccines multicentre study vaccine effectiveness |
| id |
ES_e72a3c69e8bf4c3a92c6b80fd4e178f7 |
|---|---|
| oai_identifier_str |
oai:docusalut.com:20.500.13003/25248 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24Kissling, EstherMaurel, MarinePozo, FranciscoPérez-Gimeno, GloriaBuda, SilkeSève, NoémieDomegan, LisaHooiveld, MariëtteOroszi, BeatrixMartínez-Baz, IvánGuiomar, RaquelLatorre-Margalef, NeusMlinarić, IvanLazar, MihaelaGimenez Duran, JaumeDürrwald, RalfEnouf, VincentMcKenna, Adelede Lange, MaritTúri, GergőTrobajo-Sanmartín, CaminoGomez, VerónicaSamuelsson Hagey, ToveVišekruna Vučina, VesnaCherciu, Maria CarmenGarcía Vazquez, MiriamErdwiens, AnnikaMasse, ShirleyBennett, CharleneMeijer, AdamKristóf, KatalinCastilla, JesúsRodrigues, Ana PaulaKurečić Filipović, SanjaIvanciuc, Alina ElenaBacci, SabrinaKaczmarek, MarlenaAdolescentAdultAgedChildChild, PreschoolEuropeFemaleHumansInfantInfluenza A Virus, H1N1 SubtypeInfluenza B virusInfluenza VaccinesInfluenza, HumanMaleMiddle AgedPrimary Health CareVaccinationVaccine EfficacyYoung AdultAdolescenteAdultoAncianoNiñoPreescolarEuropa (Continente)FemeninoHumanosLactanteSubtipo H1N1 del Virus de la Influenza AVirus de la Influenza BVacunas contra la InfluenzaGripe HumanaMasculinoPersona de Mediana EdadAtención Primaria de SaludVacunaciónEficacia de las VacunasAdulto JovenInfluenzacase-control studyimprintinginfluenza vaccinesmulticentre studyvaccine effectivenessIntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.Institut de veille sanitaire (France) Communicable Disease Surveillance Centre (Great Britain) European Centre for Disease Prevention and Control20252025-06-0120252025-06-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/25248reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/252482026-06-22T12:44:07Z |
| dc.title.none.fl_str_mv |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| title |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| spellingShingle |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 Kissling, Esther Adolescent Adult Aged Child Child, Preschool Europe Female Humans Infant Influenza A Virus, H1N1 Subtype Influenza B virus Influenza Vaccines Influenza, Human Male Middle Aged Primary Health Care Vaccination Vaccine Efficacy Young Adult Adolescente Adulto Anciano Niño Preescolar Europa (Continente) Femenino Humanos Lactante Subtipo H1N1 del Virus de la Influenza A Virus de la Influenza B Vacunas contra la Influenza Gripe Humana Masculino Persona de Mediana Edad Atención Primaria de Salud Vacunación Eficacia de las Vacunas Adulto Joven Influenza case-control study imprinting influenza vaccines multicentre study vaccine effectiveness |
| title_short |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| title_full |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| title_fullStr |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| title_full_unstemmed |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| title_sort |
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 |
| dc.creator.none.fl_str_mv |
Kissling, Esther Maurel, Marine Pozo, Francisco Pérez-Gimeno, Gloria Buda, Silke Sève, Noémie Domegan, Lisa Hooiveld, Mariëtte Oroszi, Beatrix Martínez-Baz, Iván Guiomar, Raquel Latorre-Margalef, Neus Mlinarić, Ivan Lazar, Mihaela Gimenez Duran, Jaume Dürrwald, Ralf Enouf, Vincent McKenna, Adele de Lange, Marit Túri, Gergő Trobajo-Sanmartín, Camino Gomez, Verónica Samuelsson Hagey, Tove Višekruna Vučina, Vesna Cherciu, Maria Carmen García Vazquez, Miriam Erdwiens, Annika Masse, Shirley Bennett, Charlene Meijer, Adam Kristóf, Katalin Castilla, Jesús Rodrigues, Ana Paula Kurečić Filipović, Sanja Ivanciuc, Alina Elena Bacci, Sabrina Kaczmarek, Marlena |
| author |
Kissling, Esther |
| author_facet |
Kissling, Esther Maurel, Marine Pozo, Francisco Pérez-Gimeno, Gloria Buda, Silke Sève, Noémie Domegan, Lisa Hooiveld, Mariëtte Oroszi, Beatrix Martínez-Baz, Iván Guiomar, Raquel Latorre-Margalef, Neus Mlinarić, Ivan Lazar, Mihaela Gimenez Duran, Jaume Dürrwald, Ralf Enouf, Vincent McKenna, Adele de Lange, Marit Túri, Gergő Trobajo-Sanmartín, Camino Gomez, Verónica Samuelsson Hagey, Tove Višekruna Vučina, Vesna Cherciu, Maria Carmen García Vazquez, Miriam Erdwiens, Annika Masse, Shirley Bennett, Charlene Meijer, Adam Kristóf, Katalin Castilla, Jesús Rodrigues, Ana Paula Kurečić Filipović, Sanja Ivanciuc, Alina Elena Bacci, Sabrina Kaczmarek, Marlena |
| author_role |
author |
| author2 |
Maurel, Marine Pozo, Francisco Pérez-Gimeno, Gloria Buda, Silke Sève, Noémie Domegan, Lisa Hooiveld, Mariëtte Oroszi, Beatrix Martínez-Baz, Iván Guiomar, Raquel Latorre-Margalef, Neus Mlinarić, Ivan Lazar, Mihaela Gimenez Duran, Jaume Dürrwald, Ralf Enouf, Vincent McKenna, Adele de Lange, Marit Túri, Gergő Trobajo-Sanmartín, Camino Gomez, Verónica Samuelsson Hagey, Tove Višekruna Vučina, Vesna Cherciu, Maria Carmen García Vazquez, Miriam Erdwiens, Annika Masse, Shirley Bennett, Charlene Meijer, Adam Kristóf, Katalin Castilla, Jesús Rodrigues, Ana Paula Kurečić Filipović, Sanja Ivanciuc, Alina Elena Bacci, Sabrina Kaczmarek, Marlena |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
|
| dc.subject.none.fl_str_mv |
Adolescent Adult Aged Child Child, Preschool Europe Female Humans Infant Influenza A Virus, H1N1 Subtype Influenza B virus Influenza Vaccines Influenza, Human Male Middle Aged Primary Health Care Vaccination Vaccine Efficacy Young Adult Adolescente Adulto Anciano Niño Preescolar Europa (Continente) Femenino Humanos Lactante Subtipo H1N1 del Virus de la Influenza A Virus de la Influenza B Vacunas contra la Influenza Gripe Humana Masculino Persona de Mediana Edad Atención Primaria de Salud Vacunación Eficacia de las Vacunas Adulto Joven Influenza case-control study imprinting influenza vaccines multicentre study vaccine effectiveness |
| topic |
Adolescent Adult Aged Child Child, Preschool Europe Female Humans Infant Influenza A Virus, H1N1 Subtype Influenza B virus Influenza Vaccines Influenza, Human Male Middle Aged Primary Health Care Vaccination Vaccine Efficacy Young Adult Adolescente Adulto Anciano Niño Preescolar Europa (Continente) Femenino Humanos Lactante Subtipo H1N1 del Virus de la Influenza A Virus de la Influenza B Vacunas contra la Influenza Gripe Humana Masculino Persona de Mediana Edad Atención Primaria de Salud Vacunación Eficacia de las Vacunas Adulto Joven Influenza case-control study imprinting influenza vaccines multicentre study vaccine effectiveness |
| description |
IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE. |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025 2025-06-01 2025 2025-06-01 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/20.500.13003/25248 |
| url |
https://hdl.handle.net/20.500.13003/25248 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Institut de veille sanitaire (France) Communicable Disease Surveillance Centre (Great Britain) European Centre for Disease Prevention and Control |
| publisher.none.fl_str_mv |
Institut de veille sanitaire (France) Communicable Disease Surveillance Centre (Great Britain) European Centre for Disease Prevention and Control |
| dc.source.none.fl_str_mv |
reponame:Docusalut instname:Conselleria de Salut i Consum del Govern de les Illes Balears |
| instname_str |
Conselleria de Salut i Consum del Govern de les Illes Balears |
| reponame_str |
Docusalut |
| collection |
Docusalut |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869422830690500608 |
| score |
15,811543 |